Alphamab Oncology Licenses Cancer Drug Candidate to Pathos AI for Up to $2.09 Billion
MT Newswires Live
Aug 05
Alphamab Oncology's (HKG:9966) wholly owned subsidiary, Jiangsu Alphamab Biopharmaceuticals, has granted Pathos AI an exclusive license to develop and commercialize cancer drug JSKN016 outside mainland China, Hong Kong, Macau and Taiwan, in a deal worth up to $2.09 billion.
Under the agreement, Alphamab will receive a $125 million upfront payment and is eligible for additional milestone payments and tiered royalties based on sales in the licensed markets, according to a Hong Kong bourse filing.
As part of the deal, Pathos AI granted Alphamab an option to invest up to $62.5 million in its preferred shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.